Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,346,957 shares of the biopharmaceutical company’s stock after selling 12,773 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Halozyme Therapeutics were worth $64,398,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in HALO. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth $29,000. GAMMA Investing LLC boosted its stake in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 350 shares during the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $57,000. FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth approximately $65,000. Finally, CWM LLC boosted its stake in Halozyme Therapeutics by 77.5% during the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 668 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HALO. JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. Finally, Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $57.10 on Friday. The stock has a fifty day moving average of $51.55 and a 200-day moving average of $54.42. The company has a market capitalization of $7.26 billion, a PE ratio of 18.91, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a one year low of $34.36 and a one year high of $65.53.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.